Coffea arabica
Coffea arabica has been studied in 4 papers since 2019: 3 trials in people, 1 review; 2 in the past year. The newest paper, Mar 22, 2026: “Coffee and Longevity: Scoping Review with ☸SAIMSARA”.
4 papers study it8 findingsUpdated
See all 4 papers on coffea arabica
At a glance
The findings reach people, from one lab or study. 2 independent labs in 3 countries.
“the CPE group showed greater reductions in total cholesterol, triglycerides, and LDL-C than the placebo group (-6.3% vs. -2.4%, p = 0.048; -12.5% vs. +1.17%, p = 0.078; and -13.7% vs. -7.1%, p = 0.01, respectively).”
None of its findings points the other way.
- 2 independent labs in 3 countries
- Funders: Auburn University and 3 more
- 4 of 8 findings with company ties
- Human trial3
Studies in people
2 studies gave coffea arabica to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases low-density lipoprotein cholesterol up: Increases high-density lipoprotein cholesterol | Randomized trial24 weeks | 79 peopleBothaged 18 years or olderPatient cohorts | Frontiers in nutrition, Mar 12, 2026 |
down: Decreases reaction time up: Increases BDNF up: Increases glutamate/GABA ratio | Randomized trialacute | older adultsOlder adults; subjective cognitive impairment | Antioxidants (Basel, Switzerland), Jan 20, 2021 |
What did studies of coffea arabica find?
6Studies of coffea arabica measured 6 outcomes, among them high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and functional connectivity.
High-density lipoprotein cholesterol
upin humans1
1 study
High-density lipoprotein cholesterol
upin humans1
Coffea arabica increases high-density lipoprotein cholesterol in humans.
“CPE product significantly reduced TC (p = 0.005), LDL-C (p < 0.0001), and TG level (p < 0.0001) but increased HDL-C level (p < 0.0001) compared to the placebo group at week 24.”
Human trial24 weeks
Frontiers in nutrition
Coffea arabica increases high-density lipoprotein cholesterol in humans (hyperlipidemia and obesity) (+7.1% vs. -5.0%, p < 0.0001).
“HDL-C increased in the CPE group but decreased in the placebo group after adjustment (+7.1% vs. -5.0%, p < 0.0001).”
Human trialhyperlipidemia and obesityproductbloodtwice daily24 weeksn = 79
Frontiers in nutrition
Low-density lipoprotein cholesterol
downin humans1
1 study
Low-density lipoprotein cholesterol
downin humans1
Coffea arabica decreases low-density lipoprotein cholesterol in humans.
“CPE product significantly reduced TC (p = 0.005), LDL-C (p < 0.0001), and TG level (p < 0.0001) but increased HDL-C level (p < 0.0001) compared to the placebo group at week 24.”
Human trial24 weeks
Frontiers in nutrition
Coffea arabica decreases low-density lipoprotein cholesterol in humans (hyperlipidemia and obesity) (-13.7% vs. -7.1%, p = 0.01).
“the CPE group showed greater reductions in total cholesterol, triglycerides, and LDL-C than the placebo group (-6.3% vs. -2.4%, p = 0.048; -12.5% vs. +1.17%, p = 0.078; and -13.7% vs. -7.1%, p = 0.01, respectively).”
Human trialhyperlipidemia and obesityproductbloodtwice daily24 weeksn = 79
Frontiers in nutrition
Functional connectivity
upin humans1
1 study
Functional connectivity
upin humans1
Coffea arabica increases functional connectivity in humans (subjective cognitive impairment).
“we found increased functional connectivity between the anterior cingulate and regions involved in sensory and decision-making networks”
Human trialsubjective cognitive impairmentanterior cingulate cortex100 mgacute
Antioxidants (Basel, Switzerland)
glutamate/GABA ratio
upin humans1
1 study
glutamate/GABA ratio
upin humans1
Coffea arabica increases glutamate/GABA ratio in humans (subjective cognitive impairment).
“we observed increased BDNF and an increased glutamate/gamma-aminobutyric acid (GABA) ratio following WCCE administration”
Human trialsubjective cognitive impairment100 mgacute
Antioxidants (Basel, Switzerland)
BDNF
upin humans1
1 study
BDNF
upin humans1
Coffea arabica increases BDNF in humans (subjective cognitive impairment).
“we observed increased BDNF and an increased glutamate/gamma-aminobutyric acid (GABA) ratio following WCCE administration”
Human trialsubjective cognitive impairment100 mgacute
Antioxidants (Basel, Switzerland)
Reaction time
downin humans1
1 study
Reaction time
downin humans1
Coffea arabica decreases reaction time in humans (subjective cognitive impairment).
“polyphenol-rich WCCE is associated with decreased reaction time and may protect against cognitive errors on tasks of working memory and response inhibition”
Human trialsubjective cognitive impairment100 mgacute
Antioxidants (Basel, Switzerland)